• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • CRO Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Trending
Hamburger Menu Hamburger Menu
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • CRO Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us

Agenus

Deal terminate tear up end deal scrap
Biotech

Incyte exits cancer pact, leaving Agenus weighing its options

The termination will give Agenus full control of assets that it will consider advancing internally or through new partnerships.
Nick Paul Taylor Feb 11, 2025 7:55am
peeling an orange

Bristol Myers culls cell therapy deals with 2 biotechs

Dec 16, 2024 11:19am
Deal terminate tear up end deal scrap

BMS ditches TIGIT, ending $200M bet on Agenus bispecific

Aug 5, 2024 9:17am
Image of a neon sign with the word no lit up next to an unlit yes

FDA wrecks Agenus’ accelerated approval plan

Jul 18, 2024 8:01am
BMS

BMS trims anti-TIGIT and a handful of other meds

Sep 14, 2023 1:57pm
graphic image of stick figures being pushed out of a line indicating theyre being removed or fired

Agenus lays off 25%, sidelines programs to focus on cancer combo

Aug 23, 2023 11:04am

Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Pharma
    • Fierce Biotech
    • Fierce Healthcare
  • Our Events
    • Life Sciences Events
©2025 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings